Stocks · News reference
JPMorgan has reiterated its 'Overweight' rating for argenx SE, maintaining a price target of 950 Euro following a review of the company's recent quarterly results.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
argenx announced that members of its management team will participate in the Guggenheim 3rd Annual Healthcare Innovation Conference and the Jefferies London Global Healthcare Conference in November 2026.
Law firm Pomerantz LLP has announced an investigation into argenx SE regarding potential securities fraud or unlawful business practices following the company's decision to discontinue a Phase 3 clinical study.
Analysts cut EAT, TTMI and MRTN targets, while raising SPOT, RBLX, S, PG and ARGX; ratings were largely maintained.
The Swiss bank UBS has increased its price target for argenx from 1300 to 1350 USD while maintaining a 'Buy' rating.
DZ Bank has increased its fair value estimate for argenx from 861 EUR to 935 EUR while maintaining a "Buy" rating.
argenx SE released its financial results for the third quarter of 2026 and provided an update on its business operations.